These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29742109)

  • 1. Effect of single-dose imipramine on chronic low-back and experimental pain. A randomized controlled trial.
    Schliessbach J; Siegenthaler A; Bütikofer L; Limacher A; Juni P; Vuilleumier PH; Stamer U; Arendt-Nielsen L; Curatolo M
    PLoS One; 2018; 13(5):e0195776. PubMed ID: 29742109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting drug efficacy in chronic low back pain by quantitative sensory tests.
    Schliessbach J; Siegenthaler A; Bütikofer L; Vuilleumier P; Jüni P; Stamer U; Arendt-Nielsen L; Curatolo M
    Eur J Pain; 2018 May; 22(5):973-988. PubMed ID: 29363217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linking altered central pain processing and genetic polymorphism to drug efficacy in chronic low back pain.
    Siegenthaler A; Schliessbach J; Vuilleumier PH; Juni P; Zeilhofer HU; Arendt-Nielsen L; Curatolo M
    BMC Pharmacol Toxicol; 2015 Sep; 16():23. PubMed ID: 26376691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative sensory tests fairly reflect immediate effects of oxycodone in chronic low-back pain.
    Schliessbach J; Siegenthaler A; Bütikofer L; Vuilleumier P; Jüni P; Arendt-Nielsen L; Curatolo M
    Scand J Pain; 2017 Oct; 17():107-115. PubMed ID: 28850362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analgesic effect of clobazam in chronic low-back pain but not in experimentally induced pain.
    Schliessbach J; Vuilleumier PH; Siegenthaler A; Bütikofer L; Limacher A; Juni P; Zeilhofer HU; Arendt-Nielsen L; Curatolo M
    Eur J Pain; 2017 Sep; 21(8):1336-1345. PubMed ID: 28418172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients.
    Schenk PW; van Fessem MA; Verploegh-Van Rij S; Mathot RA; van Gelder T; Vulto AG; van Vliet M; Lindemans J; Bruijn JA; van Schaik RH
    Mol Psychiatry; 2008 Jun; 13(6):597-605. PubMed ID: 17667959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain.
    Katz J; Pennella-Vaughan J; Hetzel RD; Kanazi GE; Dworkin RH
    J Pain; 2005 Oct; 6(10):656-61. PubMed ID: 16202958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of the extended-release tramadol hydrochloride/acetaminophen fixed-dose combination tablet for the treatment of chronic low back pain.
    Lee JH; Lee CS;
    Clin Ther; 2013 Nov; 35(11):1830-40. PubMed ID: 24183364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is low-dose amitriptyline effective in the management of chronic low back pain? Study protocol for a randomised controlled trial.
    Urquhart DM; Wluka AE; Sim MR; van Tulder M; Forbes A; Gibson SJ; Arnold C; Fong C; Anthony SN; Cicuttini FM
    Trials; 2016 Oct; 17(1):514. PubMed ID: 27770809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydromorphone extended release for neuropathic and non-neuropathic/nociceptive chronic low back pain: a post hoc analysis of data from a randomized, multicenter, double-blind, placebo-controlled clinical trial.
    Nalamachu S; Hale M; Khan A
    J Opioid Manag; 2014; 10(5):311-22. PubMed ID: 25350473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism.
    Zwisler ST; Enggaard TP; Noehr-Jensen L; Pedersen RS; Mikkelsen S; Nielsen F; Brosen K; Sindrup SH
    Basic Clin Pharmacol Toxicol; 2009 Apr; 104(4):335-44. PubMed ID: 19281600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study.
    Steigerwald I; Müller M; Davies A; Samper D; Sabatowski R; Baron R; Rozenberg S; Szczepanska-Szerej A; Gatti A; Kress HG
    Curr Med Res Opin; 2012 Jun; 28(6):911-36. PubMed ID: 22443293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.
    Fijal BA; Guo Y; Li SG; Ahl J; Goto T; Tanaka Y; Nisenbaum LK; Upadhyaya HP
    J Clin Pharmacol; 2015 Oct; 55(10):1167-74. PubMed ID: 25919121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of CYP2D6 Polymorphisms in the Outcome of Postoperative Pain Treatment.
    Seripa D; Latina P; Fontana A; Gravina C; Lattanzi M; Savino M; Gallo AP; Melchionda G; Santini SA; Margaglione M; Copetti M; di Mauro L; Panza F; Greco A; Pilotto A
    Pain Med; 2015 Oct; 16(10):2012-23. PubMed ID: 25989235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-entity hydrocodone extended-release capsules in opioid-tolerant subjects with moderate-to-severe chronic low back pain: a randomized double-blind, placebo-controlled study.
    Rauck RL; Nalamachu S; Wild JE; Walker GS; Robinson CY; Davis CS; Farr SJ
    Pain Med; 2014 Jun; 15(6):975-85. PubMed ID: 24517082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low back pain.
    Rauck RL; Potts J; Xiang Q; Tzanis E; Finn A
    Postgrad Med; 2016 Jan; 128(1):1-11. PubMed ID: 26634956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study.
    Hale ME; Dvergsten C; Gimbel J
    J Pain; 2005 Jan; 6(1):21-8. PubMed ID: 15629415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial).
    Berm EJ; Hak E; Postma M; Boshuisen M; Breuning L; Brouwers JR; Dhondt T; Jansen PA; Kok RM; Maring JG; van Marum R; Mulder H; Voshaar RC; Risselada AJ; Venema H; Vleugel L; Wilffert B
    Trials; 2015 Jan; 16():37. PubMed ID: 25636328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study.
    VanderVaart S; Berger H; Sistonen J; Madadi P; Matok I; Gijsen VM; de Wildt SN; Taddio A; Ross CJ; Carleton BC; Hayden MR; Koren G
    Ther Drug Monit; 2011 Aug; 33(4):425-32. PubMed ID: 21743374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The hypoalgesic effect of imipramine in different human experimental pain models.
    Poulsen L; Arendt-Nielsen L; Brøsen K; Nielsen KK; Gram LF; Sindrup SH
    Pain; 1995 Mar; 60(3):287-93. PubMed ID: 7596624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.